Archives of Pharmacal Research

  • 제27권2호
  • /
  • Pages.254-258
  • /
  • 2004
  • /
  • 0253-6269(pISSN)
  • /
  • 1976-3786(eISSN)
대한약학회 (The Pharmaceutical Society of Korea)
권호 표지

The Influence of Cimetidine on the Pharmacokinetics of Diltiazem and its Main Metabolite in Rabbits

  • 발행 : 2004.02.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The purpose of this study was to investigate the pharmacokinetic alteration of diltiazem and its main metabolite, deacetyldiltiazem, after oral administration of diltiazem in rabbits with or with-out cimetidine co-administration. The area under the plasma concentration-time curve (AUC) of diltiazem was significantly elevated in rabbits pretreated with cimetidine, suggesting that the oral clearance, an index of intrinsic clearance, may be decreased by the cimetidine treatment. Consistent with the increased AUC by the treatment, peak plasma concentration ($C_{max}$) for diltiazem was also elevated. Apparent volume of distribution normalized by the bioavailability (($V_{d}$/F) of diltiazem increased sigrificantly in rabbits pretreated with cimetidine increased. Taken together with the fact that the first pass metabolism for diltiazem is the primary determinant for the oral bioavailability, these observations indicate that increases in the oral clearance and (($V_{d}$/F may be a manifestation of the decreased first pass metabolism. Consistent with the hypothesis, the AUC of deacetyldiltiazem was significantly decreased in rabbits with cimetidine treatment. Ratio of deacetyldiltiazem to total diltiazem in the plasma was significantly decreased in rabbits with cimetidine treatment. These observations suggested that the metabolism of diltiazem to deacetyldiltiazem was reduced by cimetidine treatment and that the dosage of diltiazem should be adjusted when the drug is co-administered chronically with cimetidine in a clinical setting.

키워드

참고문헌

  1. Bianchetti, G., Regazzi, M., Rondanelli, R., Ascalone, V., and Morselli, P. L., Bioavailabiltity of diltiazem as a function of the administered dose. Biopharm. Drug Dispas., 12, 391-401 (1991) https://doi.org/10.1002/bdd.2510120508
  2. Choi, J. S. and Burm, J. P., Pharmacokinetics of diltiazem and deacetyldiltiazem after intravenous administration of diltiazem in mild and medium folate-induced renal failure rabbits. Kor. J. Clin. Pharm., 10, 120-124 (2000)
  3. Choi, J. S. and Burm, J. P., Pahrmacokinetics of dilitiazem and its main metabolite, deacetyldiltiazem after oral administration of diltiazem in mild and medium folate-induced renal failure rabbits. Arch. Pharm. Res., 24, 333-337 (2001) https://doi.org/10.1007/BF02975102
  4. Eichelbaum, M. and Echizen, H., Clinical pharmacology of calcium antagonists. J. Cardiovasc. Pharmacol., 6, 963-967 (1984) https://doi.org/10.1097/00005344-198400067-00006
  5. Epstein, M. and Loutzenhiser, R. D., Effects of calcium an-tagonists on renal hemodynamics. Am. J. Kidney Dis., 16, 10-14 (1990)
  6. Goebel, K. J. and Kolle, E. U., High performance liquid chromatographic dertermination of diltiazem and four of its metabolites in plasma. J. Chromatogr., 345, 355-363 (1985) https://doi.org/10.1016/0378-4347(85)80172-9
  7. Hermann, P., Rodger, S. D., Remones, G., Thenot, J. P., London, D. R., and Morselli, P. L., Pharmcokinetics of diltiazem after intravenous and oral administration. Eur. J. Clin. Pharmacol., 24, 349-352 (1983) https://doi.org/10.1007/BF00610053
  8. Homsy, W., Lefebvre, M., Caille, G., and du Souich, P., Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits. Pharm. Res., 12,609-614 (1995) https://doi.org/10.1023/A:1016226601988
  9. Johnson, L. M., Lankford, S. M., and Bai, S. A., The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing. J. Vet. Pharmacal. Ther., 18, 117-123 (1995) https://doi.org/10.1111/j.1365-2885.1995.tb00564.x
  10. Khan, A., Langley, S. J., Mullins, F. G., Dixon, J. S., and Toon, S., The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br. J. Clin. Pharmacol., 32,519-522 (1991) https://doi.org/10.1111/j.1365-2125.1991.tb03943.x
  11. Kirch, W., Ramsch, K., Janisch, H. D., and Ohnhaus, E. E., The influence of two histamine H2-receptor antagonists, cimeti-dine and ranitidine, on the plasma levels and clinical effect of nifedipine and metoprolol. Arch. Toxicol. Suppl., 7, 256-259 (1984) https://doi.org/10.1007/978-3-642-69132-4_38
  12. Knodell, R. G., Browne, D. G., Gwozdz, G. P., Brian, W. R, and Guengerich F. P., Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology, 101, 1680-1691 (1991)
  13. eboeuf, F. and Grech-Belanger, O. L., Deacetylation of diltiazem by rat liver. Drug Metab. Dispos., 15, 122-126(1987)
  14. Mikus, G., Eichelbaum, M., Fischer, C., Gumulka, S., Klotz, U., and Kroemer, H. K., Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J. Pharmacal. Exp. Ther., 253, 1042-1048 (1990)
  15. Murray, M. and Butler, A. M., Enhanced inhibition of microsomal cytochrome p450 in rat liver during diltiazem biotransforma-tion. J. Pharmcol. Exp. Ther., 279,1447-1452 (1996)
  16. Ruilope, L. M. and Alcazar, J. M., Renal effects of calcium entry blockers. Cardiovasc. Drugs Ther., 4,979-982 (1990) https://doi.org/10.1007/BF02018304
  17. Sakuma, M., Yoshikawa, M., and Sato, Y., The whole body autoradiographic studies on the disposition of 14C-labeled new 1,5-benzothiazepine derivative (14C-CRD-401) in mice. Chem. Pharm. Bull., 19,995-1005 (1971) https://doi.org/10.1248/cpb.19.995
  18. Scholz, H., Pharmacological aspects of calcium channel blockers. Cardiovasc. Drugs Ther., 10,869-872 (1997) https://doi.org/10.1007/BF00051613
  19. Schwartz, J. B., Upton, R. A., Lin, E. T., Williams, R. L., and Benet, L. Z., Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 43, 673-680 (1998) https://doi.org/10.1038/clpt.1988.94
  20. Smith, M. S., Benyunes, M. C., Bjornsson, T. D., Shand, D. G., and Pritchett, E. L., Influence of cimetidine on verapamil kinetics and dynamics. Clin. Pharmacol. Ther., 36, 551-554 (1984) https://doi.org/10.1038/clpt.1984.218
  21. Sterzel, P. B., Renal actions of calcium antagonists. J. Cardiovasc. Pharmacol., 10, 17-22 (1987) https://doi.org/10.1097/00005344-198706107-00004
  22. Sutton, D., Butler, A. M., Nadin, L., and Murray, M. L., Role of CYP3A4 in human hepatic diltiazem N-demethylation: in-hibition of CYP3A4 activity by oxidized diltiazem metabolite. J. Pharmacal. Exp. Ther., 282, 294-300 (1994)
  23. Winship, L. C., McKenney, J. M., and Wright, J. T., The effect of ranitidine and cimetidine on single-dose diltiazem pharma-cokinetics. Pharmacotherapy, 5,16-19 (1985)
  24. Yamaoka, K., Tanigawara, Y., Nakagawa. T., and Uno, T., A pharmacokinetics analysis program for microcomputer. J. Pharm. Dyn., 4, 879-883 (1971)